Actively Recruiting

Phase 4
Age: 18Years - 64Years
All Genders
NCT04373564

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Led by Guerbet · Updated on 2026-01-22

2076

Participants Needed

51

Research Sites

405 weeks

Total Duration

On this page

Sponsors

G

Guerbet

Lead Sponsor

B

Bayer AG (Sponsor)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (GBCAs) have an effect on body movement and mental skills when given to participants multiple times within 5 years. The study plans to enroll about 2076 participants suffering from a condition for which they are likely to have at least annually a MRI or another imaging examinations. Only adults up to 65 years will be considered to join this study. During the study duration of 5 years participants will receive annually a MRI or other imaging tests (such as CT-scan, x-ray) and will visit the study doctor at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills.

CONDITIONS

Official Title

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Who Can Participate

Age: 18Years - 64Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant must be neurologically normal, confirmed by a normal neurologic exam at screening
  • Participant agrees to have unenhanced MRI of the brain at enrollment and at 5 years
  • Participants must have one of the following: medium to high breast cancer risk or dense breasts needing MRI screening, elevated PSA under prostate cancer surveillance, chronic liver disease for liver cancer surveillance, low-grade colorectal or neuroendocrine tumors for liver metastases screening, or small pancreatic IPMN under imaging surveillance
  • GBCA-exposed participants should likely have at least 5 GBCA-enhanced MRI exams annually with the same GBCA over 5 years
  • Participants with up to 3 prior documented GBCA administrations with the same GBCA are eligible
  • Control participants must have no prior or planned GBCA exposure during the study
  • Control participants must be willing to undergo unenhanced brain MRI at baseline and year 5 and clinical imaging as needed in years 1 to 4
Not Eligible

You will not qualify if you...

  • History or current neurological or psychiatric diseases affecting motor or cognitive tests, including cerebrovascular disease, multiple sclerosis, neurodegenerative diseases, malignant diseases other than listed, carcinoid tumors, epilepsy, prior neurosurgery, psychotic disorders, major depression or bipolar disorder within recent years, neurodevelopmental disorders, uncontrolled severe migraine, recent anxiety or depression, or low cognitive screening scores
  • Prior, planned, or ongoing chemotherapy or brain irradiation
  • Use of medications affecting neuro-cognitive or motor function
  • Substance or alcohol abuse
  • Alcoholic cirrhosis
  • Kidney disease with eGFR less than 60 mL/min/1.73 m2
  • Exposure to chemicals affecting cognitive or motor function such as heavy metals, pesticides, solvents, or carbon monoxide
  • Need for more than one contrast-enhanced MRI every 6 months
  • Pregnant or nursing women
  • Presence of metal-containing joint implants or prostheses
  • For GBCA arms: prior receipt of a different GBCA before study entry
  • For control arm: any prior GBCA exposure or contraindications to unenhanced MRI examinations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 51 locations

1

Scottsdale Medical Imaging, LLC

Scottsdale, Arizona, United States, 85260

Actively Recruiting

2

Yale University School of Medicine

New Haven, Connecticut, United States, 06520

Withdrawn

3

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

Actively Recruiting

4

Methodist Medical Center of Illinois

Peoria, Illinois, United States, 61637

Actively Recruiting

5

Massachussets General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

6

Boston University Medical Center

Boston, Massachusetts, United States, 02118

Terminated

7

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Withdrawn

8

ActivMed Practices & Research, Inc.

Methuen, Massachusetts, United States, 01844

Withdrawn

9

University of Massachusetts Memorial Medical Center

Worcester, Massachusetts, United States, 01655

Terminated

10

Department of Radiology

St Louis, Missouri, United States, 63110

Withdrawn

11

UNC School of Medicine

Chapel Hill, North Carolina, United States, 27599

Withdrawn

12

Penn State Hershey Medical Center

Hershey, Pennsylvania, United States, 17033

Actively Recruiting

13

Albert Einstein Healthcare Network

Philadelphia, Pennsylvania, United States, 19141

Actively Recruiting

14

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

15

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Withdrawn

16

University of Wisconsin

Madison, Wisconsin, United States, 53792

Actively Recruiting

17

Hospital Santa Marta

Taguatinga, Federal District, Brazil, 72025-110

Terminated

18

Liga Norte-Rio-Grandense Contra o Câncer

Natal, Rio Grande do Norte, Brazil, 59075-740

Withdrawn

19

Instituto Mederi de Pesquisa e Saude

Passo Fundo, Rio Grande do Sul, Brazil, 99010-120

Actively Recruiting

20

Hospital Moinhos de Vento

Porto Alegre, Rio Grande do Sul, Brazil, 90035-001

Actively Recruiting

21

Instituto Baía Sul de Ensino e Pesquisa (IEP)

Florianópolis, Santa Catarina, Brazil, 88020-210

Withdrawn

22

CEMEC - Oncológica

São Bernardo do Campo, São Paulo, Brazil, 09715-090

Withdrawn

23

Fundação Faculdade Regional de Medicina de São José do Rio Preto

São José do Rio Preto, São Paulo, Brazil, 15090-000

Actively Recruiting

24

CPCLIN - Centro de Pesquisas Clínicas Ltda.

São Paulo, São Paulo, Brazil, 01228-200

Terminated

25

Albert Einstein Sociedade Beneficente Israelita Brasileira

São Paulo, São Paulo, Brazil, 05652000

Actively Recruiting

26

CEMEC - Oncológica

São Bernardo do Campo, Brazil

Withdrawn

27

G. Kenneth Jansz Medical Professional Corporation

Burlington, Ontario, Canada, L7N 3V2

Withdrawn

28

Groupe Hospitalier Pitie-Salpetriere

Paris, France, 75013

Withdrawn

29

CHU Strasbourg - Hôpital Hautepierre

Strasbourg, France, 67200

Actively Recruiting

30

Universitaetsklinikum Tuebingen

Tübingen, Baden-Wurttemberg, Germany, 72076

Active, Not Recruiting

31

Vivantes Klinikum Neukoelln

Berlin, Germany, 12351

Actively Recruiting

32

A.O.U. Senese Policlinico Santa Maria alle Scotte

Siena, Siena, Italy, 53100

Actively Recruiting

33

Azienda Ospedaliera Universitaria di Trieste

Trieste, Trieste, Italy, 34125

Actively Recruiting

34

Ospedale San Raffaele

Milan, Italy, 20123

Actively Recruiting

35

Università Campus Bio-Medico di Roma

Roma, Italy, 00128

Actively Recruiting

36

Azienda Ospedaliera Universitaria Integrata Verona (Ospedale Borgo Roma)

Verona, Italy, 37134

Actively Recruiting

37

BHI of Omsk region "Clinical Oncology Dispensary"

Omsk, Russia, 644013

Suspended

38

FSBI "National medical scientific center of psychiatry and neurology n.a. V.M. Bekhterev" Adolescent

Saint Petersburg, Russia, 192019

Suspended

39

FSBI North-West Federal Medical Research Center n.a. V.A. Almazov of MoH RF

Saint Petersburg, Russia, 197341

Suspended

40

LLC Medical Center Mart

Saint Petersburg, Russia, 199178

Suspended

41

RSBIH "Smolensk Regional Clinical Hospital"

Smolensk, Russia, 214019

Suspended

42

Federal State Budgetary Scientific Institution "Tomsk National Research Medical Centre of the Russia

Tomsk, Russia, 634009

Suspended

43

SBIH Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan

Ufa, Russia, 450054

Suspended

44

Hallym University Chuncheon Sacred Heart Hospital

Chuncheon, Gangwon-do, South Korea, 24253

Withdrawn

45

Chonnam National University Hospital

Gwangju, Gyeonggi-do, South Korea, 61469

Withdrawn

46

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea, 13620

Actively Recruiting

47

Inje University Busan Paik Hospital

Busan, South Korea, 47392

Actively Recruiting

48

Pusan National University Hospital

Busan, South Korea, 49241

Actively Recruiting

49

Chosun University Hospital

Gwangju, South Korea, 61453

Actively Recruiting

50

Gangnam Severance Hospital, Yonsei University Health System

Seoul, South Korea, 06273

Actively Recruiting

51

Chung-Ang University Hospital

Seoul, South Korea, 06973

Actively Recruiting

Loading map...

Research Team

N

Nathalie LE FUR, PhD

CONTACT

F

Frantz HEBERT

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years | DecenTrialz